One afternoon in May, Michael Joseph Smith, a pediatric infectious disease specialist, strides in baseball-patterned socks through a Duke University facility in Durham, N.C., to welcome Cameron O’Hara, a 14-year-old vaccine trial subject. Smith has been acting as co-principal investigator at one of the sites that’s been testing the Pfizer-BioNTech vaccine in kids since last winter. O’Hara and his mother have come to the office following the “unblinding” process—in which he’d learned, to his disappointment, that he’s been getting a placebo—to get his first dose of the real thing. He crosses his sneakers and grips his mom’s hand as the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.